GEP-NET Treatment
Nov 01, 2024
Gastroenteropancreatic Neuroendocrine Tumours Market To Gain Substantial Momentum With Entrance of Novel Therapies
A Neuroendocrine tumor is a type of cancer where neuroendocrine cells develop into tumors. Whereas Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. A Neuroendocrine Tumor grows slowly and aggressively and tends to spread to other parts of the body. ...
Read More...
Apr 26, 2024
Novartis’ LUTATHERA for GEP-NET Treatment: Ray of Hope for Pediatric Patients
2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects. On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
